Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in the United States. On September 11, 2009, the U.S.

More here: 
Theravance And Astellas Announce The Commercial Launch Of VIBATIVTM (telavancin) In The United States

Related posts:

1. Down Syndrome Prevalence In The United StatesDown syndrome is a chromosomal disorder that affects an estimated 1 in 800 births or 5,400 infants in the United States each year. The chance of surviving beyond the first...
2. United States Olympic Committee Announces D.I.S.C. Sports And Spine Center As An Official Medical Services ProviderThe United States Olympic Committee (USOC) and D.I.S.C. Sports and Spine Center today officially announced a strategic partnership in which D.I.S.C. will become an Official Medical Services Provider through the...
3. Trubion And Facet Biotech Announce Presentation Of Positive TRU-016 Data At The 2009 ASH Annual MeetingTrubion Pharmaceuticals, Inc. (Nasdaq: TRBN) and Facet Biotech Corp. (Nasdaq: FACT) announced the presentation of positive data from a phase 1 study of TRU-016 in patients with relapsed and refractory...
4. Ambit Biosciences And Astellas Enter Strategic Partnership To Research, Develop And Commercialize FLT3 Kinase Inhibitors In Multiple IndicationsAmbit Biosciences Corporation and Astellas Pharma Inc. announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. This...
5. Severity Of Swine Flu In The United StatesResearch published this week in PLoS Medicine presents the most accurate assessment to date of the severity of the swine flu (H1N1) pandemic in the US. Scientists need to measure...
6. Astellas Award For Blindness Prevention Research Received By University Of Maryland ChemistFredrick Khachik, Ph.D., a senior research scientist in the Department of Chemistry and Biochemistry at the University of Maryland, College Park, has been chosen to receive a 2009 Astellas USA...
7. Astellas Award For Arsenic Groundwater Remediation Efforts Received By Lehigh University ProfessorArup K. SenGupta, Ph.D., a professor of civil, environmental and chemical engineering at Lehigh University in Bethlehem, Pa., has been chosen to receive a 2009 Astellas USA Foundation Award. The...
8. UN Secretary-General Urges Countries To Follow The United States And Lift Travel Restrictions For People Living With HIVUNAIDS welcomes President Obama's announcement of the final rule removing entry restrictions based on HIV status from US policy. The removal of HIV-related travel restrictions in the US overturns a...
9. List Of The Top Health Insurance Providers In The United StatesWhen it comes to health management insurance the organization you choose is vital. The difference in how corporations treat their design holders can be very different. Finding a health insurance...
10. Jobs For Hospitalist In The United States.Healthcare industry of United States provides variety of opportunities for different healthcare professionals from various medical facilities from all parts of the world. A Hospitalist is the one who concerned...
11. Swish And Enviro-Solutions To Launch SDC-Based Disinfectants In Canada And USPURE Bioscience (NASDAQ:PURE) announced an agreement with Charlotte Products Ltd. whereby Charlotte Products will blend and package PURE's patented silver dihydrogen citrate (SDC)-based hard surface disinfectant, which will be distributed...
12. Sanofi-aventis And Medicines For Malaria Venture To Launch The Largest Ever Study Of An Antimalarial DrugSanofi-aventis ( EURONEXT: SAN and NYSE: SNY) and Medicines for Malaria Venture (MMV) announced that they have entered an agreement to launch the largest safety and efficacy study of an...
13. AHRA And Toshiba Announce 2009 Putting Patients First Grant RecipientsRecognizing the need for programs that improve patient safety and quality care, AHRA: The Association for Medical Imaging Management and Toshiba America Medical Systems, Inc. announced the six recipients of...
14. Genentech And Biogen Idec Announce Positive Results From First Phase III Trial Of Ocrelizumab In Rheumatoid ArthritisGenentech, Inc. a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today a Phase III study (STAGE) of the investigational...
15. Roche, Genentech And Biogen Idec Announce Positive Results From First Phase III Trial Of Ocrelizumab In Rheumatoid ArthritisRoche (SIX: RO, ROG; OTCQX: RHHBY), Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec (Nasdaq: BIIB) announced a Phase III study (STAGE) of the investigational...